Description:
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of
Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of
TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous
esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).
Title
- Brief Title: A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
- Official Title: An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
TAK-931-2001
- SECONDARY ID:
U1111-1192-7975
- SECONDARY ID:
JapicCTI-163200
- NCT ID:
NCT03261947
Conditions
- Metastatic Pancreatic Cancer
- Colorectal Cancer
- Esophageal Neoplasms
- Carcinoma, Non-small-cell Lung
Interventions
Drug | Synonyms | Arms |
---|
TAK-931 | | TAK-931 |
Purpose
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of
Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of
TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous
esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).
Detailed Description
Pancreatic Arm Now Closed.
The drug being tested in this study is called TAK-931. TAK-931 blocks function of a specific
protein called CDC7 kinase in the human body. TAK-931 is being tested in participants with
metastatic cancer (colorectal, pancreatic, sqNSCLC and sqEC) in the United States and Japan
and also in the participants with any type of metastatic cancer with no standard therapeutic
alternative in the United States only. This study will look at the safety, tolerability and
pharmacokinetics of TAK-931.
The study will enroll approximately 160 participants. Participants will be enrolled in 5
cohorts: 1) Western safety cohort, to be enrolled in the United States only, will include
non-Japanese participants with metastatic solid tumors and no standard therapeutic
alternative, 2) Metastatic pancreatic cancer cohort, 3) Metastatic colorectal cancer cohort,
4) Metastatic sqNSCLC cohort, and 5) Metastatic sqEC cohort. All participants will receive:
• TAK-931 50 mg capsules
All participants will be asked to take one 50 mg capsule at the same time of the day every
day for 14 days, followed by 7 days break in 21-day cycles throughout the study.
This multi-center trial will be conducted in the United States and Japan. The overall time to
participate in this study is approximately 24 months. Participants will make multiple visits
to the clinic. Participants in both Western cohort and disease specific cohorts will be
followed for progression-free survival every 12 weeks after the last dose of the study drug
until the occurrence of disease progression, loss to follow up, consent withdrawal, death,
start of subsequent antineoplastic therapy, study termination, or until 6 months after
discontinuation of the study treatment, whichever occurs first. Once disease progression is
confirmed, participants in the disease-specific cohorts will be followed for overall survival
every 12 weeks until death, loss to follow up, consent withdrawal, study termination, or
transfer of a participant to a long term safety study, single participant investigational new
drug application, or similar program after the last dose of the study drug.
Trial Arms
Name | Type | Description | Interventions |
---|
TAK-931 | Experimental | TAK-931 50 milligram (mg), capsules, orally, once daily for 14 days, followed by 7-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 1 year). | |
Eligibility Criteria
Inclusion Criteria:
1. Adult male or female participants aged >=20 years (Japan) or >=18 years (United
States).
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
3. Has pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed
after, at least, a first line of standard systemic chemotherapy for the metastatic
disease, OR participants with pathologically confirmed metastatic adenocarcinoma of
the colon or rectum who have progressed to at least 2 lines of standard systemic
chemotherapy for the metastatic disease, OR participants with pathologically confirmed
locally advanced or metastatic sqEC that has progressed after at least a first line of
standard systemic therapy for metastatic disease. First-line participants can be
enrolled if a platinum doublet is contraindicated or refused by the participants, OR
pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed
after at least 2 lines of standard systemic therapy for metastatic disease.
4. For the Western safety cohort only: participants with locally advanced or metastatic
solid tumor for whom no standard treatment with an established survival benefit is
available or if the participant refuses other standard therapy.
5. For disease-specific cohort participants: measurable disease per RECIST v. 1.1
6. Left ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA
scan within 4 weeks before receiving the first dose of study drug.
7. Recovered to Grade 1 or baseline from all toxic effects of previous therapy (except
alopecia or neuropathy).
8. Suitable venous access for the study-required blood sampling.
9. For the Western safety cohort only: willingness to undergo serial skin tissue
biopsies.
10. For disease-specific cohort participants: Must have an archival (banked) tumor sample
or agree to have a new (fresh) tumor biopsy during the screening period. If a new
tumor sample is needed, the disease should be accessible for a nonsignificant risk
biopsy procedure (those occurring outside the brain, lung/mediastinum, and pancreas,
or obtained with endoscopic procedures not extending beyond the stomach or bowel). For
participants in the Western safety cohort, this biopsy is optional.
Exclusion Criteria:
1. Participants who require continuous use of proton pump inhibitors (PPIs) or
histamine-2 (H2) receptor antagonists and participants who are taking PPIs within 5
days before the first dose of study drug.
2. Treatment with clinically significant enzyme inducers, such as phenytoin,
carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, or Saint John's wort
within 14 days before the first dose of study drug.
3. Treatment with any systemic anticancer treatment (including investigational products)
within 30 days or 5 half-lives, whichever is shorter, before the first dose of study
drug.
4. History of any of the following within the last 3 months before administration of the
first dose of study drug:
- Ischemic myocardial event including angina requiring therapy and artery
revascularization procedures, myocardial infarction, and unstable symptomatic
ischemic heart disease.
- Ischemic cerebrovascular event, including transient ischemic attack and artery,
revascularization procedures.
- Significant, uncontrolled cardiac arrhythmia (including atrial
flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).
- New York Heart Association Class III to IV heart failure.
- Any other cardiac condition that, in the opinion of the investigator, could pose
an additional risk for participation in the study (example, pericardial effusion
or restrictive cardiomyopathy).
- Baseline prolongation of the QT interval corrected for heart reate (HR) using
Fridericia's formula (QT interval corrected for heart rate using Fridericia's
formula (QTcF); example, repeated demonstration of QTcF interval >480 millisecond
(ms), history of congenital long QT syndrome, or torsades de pointes).
5. Hypertension that is unstable or not controlled by medication.
6. History of uncontrolled brain metastasis unless:
- Previously treated with surgery, whole-brain radiation, or stereotactic
radiosurgery, and
- Stable disease (SD) for >=30 days, without steroid use (or stable steroid dose
established for >=14 days before the first dose of TAK-931).
7. Known history of human immunodeficiency virus infection.
8. Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C
virus (HCV) infection viral load. Note: Participants who have positive HBV core
antibody or HBV surface antigen antibody can be enrolled but must have an undetectable
HBV viral load.
9. Prior treatment with radiation therapy involving >=25% of the hematopoietically active
bone marrow within 3 months before the first dose of study drug.
10. Participants with known microsatellite instability-high (MSI-H) genotype or known wild
type tumor protein 53 (TP53) per local testing.
11. Western Safety Cohort Only: Participants with Japanese heredity.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Percentage of Participants with Dose Limiting Toxicities (DLTs) in Western Safety Cohort |
Time Frame: | Baseline up to 1 year |
Safety Issue: | |
Description: | DLT includes: Non-febrile Grade 4 neutropenia, Febrile neutropenia: Grade greater than or equal to (>=) 3 neutropenia, Grade 4 thrombocytopenia, grade >=3 thrombocytopenia of any duration accompanied by grade 2 bleeding or requiring transfusion, delay in the initiation of cycle 2 by more than 14 days due to a lack of adequate recovery of treatment-related hematological or nonhematologic toxicities, grade 2 ejection fraction decreased by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, Grade 4 laboratory abnormalities, other grade 2 nonhematologic toxicities that are considered by the investigator to be related to study drug and dose-limiting, participants receiving less than (<) 50 percent (%) of doses (<7 doses) of the planned TAK-931 dosing in cycle 1 due to study drug-related adverse events (AEs), grade >=3 nonhematologic toxicity with the few exceptions: Grade 3 arthralgia/ myalgia, fatigue, laboratory abnormalities, nausea and/or emesis or diarrhea. |
Secondary Outcome Measures
Measure: | Cmax: Maximum Observed Plasma Concentration for TAK-931 |
Time Frame: | Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 |
Time Frame: | Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-931 |
Time Frame: | Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-931 |
Time Frame: | Cycle 1 Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | CLr: Renal Clearance of TAK-931 |
Time Frame: | Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | CLr is a measure of apparent clearance of the drug from the urine. The clearance is the rate at which waste substances are cleared from the blood. |
Measure: | t1/2z: Terminal disposition phase half-life |
Time Frame: | Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | CLss/F: Steady-state Apparent Oral Clearance |
Time Frame: | Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by AUC expressed in liters/hour (L/hr). |
Measure: | Rac(AUC): Accumulation Ratio Based on AUC Over the Dosing Interval (AUCτ) |
Time Frame: | Cycle 1 Day 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose |
Safety Issue: | |
Description: | |
Measure: | Overall Response Rate (CR and PR) |
Time Frame: | Baseline up to 1 year |
Safety Issue: | |
Description: | Overall Response rate is defined as the sum of percentage of participants with complete response rate and partial response rate. Response and progression was evaluated in this study Per RECIST V1.1 where CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
Measure: | Duration of Response (DOR) |
Time Frame: | Baseline up to 1 year |
Safety Issue: | |
Description: | DOR is defined as the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression. Per RECIST V1.1, CR is defined as disappearance of all lesions, PR is defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD. PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
Measure: | Progression Free Survival (PFS) |
Time Frame: | From randomization until disease progression or death whichever occurs first (up to 1 year) |
Safety Issue: | |
Description: | PFS is defined as time from start of study treatment to first documentation of disease progression or death due to any cause, whichever occurs first Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
Measure: | Overall Survival (OS) |
Time Frame: | Baseline up to 1 year |
Safety Issue: | |
Description: | OS is the time from start of study treatment to date of death due to any cause. |
Measure: | Percentage of Participants with TEAEs in the Tumor-Specific Cohorts |
Time Frame: | Baseline up to 1 year |
Safety Issue: | |
Description: | Percentage of participants with Grade >=3 TEAEs, SAEs, TEAEs leading to treatment discontinuation or dose modifications, and clinically significant changes in laboratory values and vital sign measurements in the tumor-specific cohorts will be reported. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Millennium Pharmaceuticals, Inc. |
Trial Keywords
Last Updated
October 5, 2020